Gardner Lewis Asset Management L P Cerevel Therapeutics Holdings, Inc. Transaction History

Gardner Lewis Asset Management L P

  • $353 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$38.96 - $42.75 $2.73 Million - $2.99 Million
70,000 Added 57.31%
192,150 $7.86 Million
Q1 2024

May 13, 2024
BUY
$40.88 - $43.27 $4.99 Million - $5.29 Million
122,150 New
122,150 $5.16 Million

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Gardner Lewis Asset Management L P Portfolio

Follow Gardner Lewis Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gardner Lewis Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Gardner Lewis Asset Management L P with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email